trending Market Intelligence /marketintelligence/en/news-insights/trending/ebwcvwe5mdoalmpijpzksw2 content esgSubNav
In This List

Unum Therapeutics files for IPO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Unum Therapeutics files for IPO

Unum Therapeutics Inc. plans to offer up to about $86.3 million of its common shares through an IPO.

The company plans to list its stock on the Nasdaq Global Market under the symbol UNUM.

Morgan Stanley & Co. LLC, Cowen and Co. LLC and Wedbush Securities Inc. are underwriting the IPO.

Cambridge, Mass.-based Unum Therapeutics develops a proprietary therapy for multiple cancers.

The company's antibody-coupled T-cell receptor, or ACTR protein, kills tumors identified by separately administered antibodies. Unum Therapeutics expects the ACTR platform to universally treat cancers, as it is not bound to a single type of tumor-targeting antibody.